Clinical Trial

The Safety and Efficacy of Benmelstobart Injection in Patients With Advanced Biliary Tract Malignant Tumors

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated August 7, 2025 (before its estimated August 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
Evaluate the progression-free survival (PFS) of benmelstobart combined with gemcitabine and cisplatin in first-line patients with advanced cholangiocarcinoma, and the progression-free survival (PFS) of benmelstobart combined with anlotinib in second-line patients with advanced cholangiocarcinoma.
Trial Details
NCT Number NCT07109167
Lead Sponsor The Second Affiliated Hospital of Shandong First Medical University
Conditions Biliary Tract Neoplasms
Enrollment 30 participants
Start Date 2025-08-01
Primary Completion 2026-08-01 (estimated)
Study Completion 2027-08-01 (estimated)
Updated on ClinicalTrials.gov 2025-08-07